Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers


  Hepatitis C

  Free Subscription


1 Eur J Gastroenterol Hepatol
2 Gut
1 Hepatology
2 J Viral Hepat
1 PLoS One
1 Scand J Gastroenterol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Eur J Gastroenterol Hepatol

  1. HINRICHSEN H, Stoehr A, Cornberg M, Klinker H, et al
    Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    Eur J Gastroenterol Hepatol. 2020 Apr 25. doi: 10.1097/MEG.0000000000001759.
    PubMed         Abstract available


  2. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.

  3. LUTCKII A, Strunz B, Zhirkov A, Filipovich O, et al
    Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus.
    Gut. 2020 Apr 27. pii: gutjnl-2019-320269. doi: 10.1136/gutjnl-2019-320269.
    PubMed         Abstract available


  4. NAZZAL M, Sur S, Steele R, Khatun M, et al
    Establishment of a PDX tumor from Hepatitis C Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.
    Hepatology. 2020 May 1. doi: 10.1002/hep.31298.
    PubMed         Abstract available

    J Viral Hepat

  5. CARRASCO I, Sainz T, Antoinette Frick M, de Ory SJ, et al
    Response to Direct Acting Antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients.
    J Viral Hepat. 2020 Apr 29. doi: 10.1111/jvh.13308.
    PubMed         Abstract available

  6. CHIU WN, Hung CH, Lu SN, Chen MY, et al
    Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection:a multicenter pooled analysis in Taiwan.
    J Viral Hepat. 2020 Apr 28. doi: 10.1111/jvh.13305.
    PubMed         Abstract available

    PLoS One

  7. WON YK, Kang KS, Gonzalez YS, Razavi H, et al
    A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    PLoS One. 2020;15:e0232186.
    PubMed         Abstract available

    Scand J Gastroenterol

  8. KABERG M, Larsson SB, Jerkeman A, Nystedt A, et al
    High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder.
    Scand J Gastroenterol. 2020 May 1:1-7. doi: 10.1080/00365521.2020.1754456.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.